These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 24575543)

  • 21. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic castration-resistant prostate cancer: time for innovation.
    Tucci M; Scagliotti GV; Vignani F
    Future Oncol; 2015; 11(1):91-106. PubMed ID: 25572785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New agents for the management of castration-resistant prostate cancer.
    Cersosimo RJ
    Ann Pharmacother; 2012 Nov; 46(11):1518-28. PubMed ID: 23136351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
    Galletti G; Leach BI; Lam L; Tagawa ST
    Cancer Treat Rev; 2017 Jun; 57():16-27. PubMed ID: 28527407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
    Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug therapies for metastatic castration-resistant prostate cancer.
    El-Bahesh E; Finianos A; Alfaraj A; Aragon-Ching JB
    Future Oncol; 2015; 11(17):2395-403. PubMed ID: 26274603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).
    Lee DJ; Cha EK; Dubin JM; Beltran H; Chromecki TF; Fajkovic H; Scherr DS; Tagawa ST; Shariat SF
    BJU Int; 2012 Apr; 109(7):968-85. PubMed ID: 22035221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New therapy concepts for castration-resistant prostate cancer: between hormone manipulation, targeted therapy and chemotherapy].
    Kübler H; Miller K
    Urologe A; 2013 Nov; 52(11):1517-8, 1520-1, 1524-6 passim. PubMed ID: 24166056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.
    Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):192-205. PubMed ID: 21577234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
    Bracarda S; Sisani M; Marrocolo F; Hamzaj A; Del Buono S; Altavilla A
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1283-94. PubMed ID: 25353258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
    Recine F; Ceresoli GL; Baciarello G; Cerbone L; Calabrò F
    Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):400-10. PubMed ID: 26337241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Sequencing and combination of agents in castration resistant prostate cancer.].
    Ojeda AV; Ledo MJ; Alvarez-Ossorio JL
    Arch Esp Urol; 2018 Sep; 71(8):711-720. PubMed ID: 30319131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.
    Garcia JA; Rini BI
    Cancer; 2012 May; 118(10):2583-93. PubMed ID: 22038761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of patients with castration-resistant disease.
    Pezaro C; Omlin A; Lorente D; de Bono J
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1243-60, ix. PubMed ID: 24188261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New and emerging agents for the treatment of castration-resistant prostate cancer.
    Higano CS; Crawford ED
    Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
    Bracarda S; Logothetis C; Sternberg CN; Oudard S
    BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
    Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
    Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Second line therapy for castration-resistant prostate cancer (CRPC)].
    Molitor B; Börgermann C
    Urologe A; 2012 Mar; 51(3):357-62. PubMed ID: 22113549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy-based treatment for castration-resistant prostate cancer.
    Seruga B; Tannock IF
    J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.